An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in the US – is also safe and generates a strong antibody response in
Emergent BioSolutions, one of only three companies with a vaccine for mpox, has agreed to donate 50,000 doses of its shot for use in the current outbreak concentrated in central Africa, but
Bavarian Nordic will get an accelerated review of its chikungunya vaccine CHIKV VLP at the EMA, as it tries to chase down a lead held by rival Valneva.